Paper Details

  1. Home
  2. Paper Details

Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation.

Author: FukamiTatsuki, HosomiHiroko, IwamuraAtsushi, NakajimaMiki, YokoiTsuyoshi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study constructed a cell-based system to evaluate the cytotoxicity of reactive metabolites produced by CYP3A4. The study found that HepG2 cells showed the highest CYP3A4 protein expression and activity among seven hepatoma cell lines. The cytotoxicity of 23 drugs was evaluated in AdCYP3A4-infected HepG2 cells, with 11 drugs showing significant decrease in cell viability.
Paper Details　
Original Abstract of the Article :
Drug-induced hepatotoxicity, which is a rare but serious adverse reaction to a large number of pharmaceutical drugs, is sometimes associated with reactive metabolites produced by drug-metabolizing enzymes. In the present study, we constructed a cell-based system to evaluate the cytotoxicity of react...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1124/dmd.110.037077

データ提供：米国国立医学図書館（NLM）

CYP3A4-Mediated Metabolic Activation: Uncovering the Hidden Dangers in the Desert of Drug Development

This research delves into the crucial area of drug development, focusing on the potential toxicity of reactive metabolites produced by drug-metabolizing enzymes, particularly CYP3A4. The study describes the development of a highly sensitive cytotoxicity assay system to evaluate the cytotoxic effects of reactive metabolites produced by CYP3A4. This innovative system utilizes human hepatoma cells expressing CYP3A4 and provides a valuable tool for preclinical drug screening, allowing for the identification of potentially toxic compounds and mitigating the risk of drug-induced hepatotoxicity.

Navigating the Complexities of Drug Metabolism and Toxicity

This research highlights the importance of understanding the complex interplay between drug metabolism and toxicity, particularly the role of CYP3A4 in producing reactive metabolites. The study's development of a sensitive cytotoxicity assay system provides a crucial tool for preclinical drug screening, helping to identify potentially toxic compounds and minimize the risk of drug-induced hepatotoxicity. This journey through the desert of drug development requires a thorough understanding of the potential risks and benefits of different drug candidates to ensure safe and effective therapies.

The Importance of Preclinical Drug Screening

This research underscores the importance of comprehensive preclinical drug screening to identify potential toxicities and minimize the risk of adverse drug reactions. The study's development of a sensitive cytotoxicity assay system provides a valuable tool for drug developers, enabling them to evaluate the potential toxicity of drugs early in the development process. This journey through the desert of drug development requires a vigilant approach, combining scientific rigor with a commitment to patient safety to ensure the development of safe and effective therapies.

Dr. Camel's Conclusion

This research provides a valuable tool for navigating the complex landscape of drug development, highlighting the importance of understanding the potential toxicity of reactive metabolites produced by drug-metabolizing enzymes, particularly CYP3A4. The development of a sensitive cytotoxicity assay system offers a crucial step towards ensuring the safety and efficacy of new drugs, ultimately protecting patients and improving health outcomes.
Date :
  1. Date Completed 2011-12-09
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

21540358

DOI: Digital Object Identifier

10.1124/dmd.110.037077

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.